Ildikó Madurka

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Ildikó Madurka, Alexander Vishnevsky, Joan B. Soriano et al. · Infection · 2022 · 77 citations · Full text

New Oral Nlrp3, Early Phase 2A, Antiviral Therapy +4

Different Trends in Excess Mortality in a Central European Country Compared to Main European Regions in the Year of the COVID-19 Pandemic (2020): a Hungarian Analysis

Krisztina Bogos, Zoltán Kiss, Anna Kerpel Fronius et al. · Pathology & Oncology Research · 2021 · 33 citations · Full text

The effectiveness of pulmonary rehabilitation in connection with lung transplantation in Hungary

Mária Kerti, Anikó Bohács, Ildikó Madurka et al. · Annals of Palliative Medicine · 2021 · 19 citations · Full text

SOLUBLE INTERLEUKIN 6 (IL-6) RECEPTOR INFLUENCES THE EXPRESSION OF THE PROTOONCOGENE junB AND THE PRODUCTION OF FIBRINOGEN IN THE HepG2 HUMAN HEPATOMA CELL LINE AND PRIMARY RAT HEPATOCYTES

Péter Igaz, Sára Tóth, Stefan Rose‐John et al. · Cytokine · 1998 · 15 citations

Inflammation, Cytokine, Soluble Interleukin 6 +14